A landmark randomized clinical trial has definitively demonstrated a substantial decrease in serious cardiovascular complications for individuals diagnosed with atrial fibrillation (AF) who are deemed to be at an intermediate risk of experiencing a stroke. This pivotal research, presented at the prestigious ESC Congress 2026 and concurrently published in the esteemed New England Journal of Medicine, provides compelling evidence that the initiation of modern oral anticoagulant therapy can significantly outperform the absence of such treatment in preventing adverse clinical outcomes.
Atrial fibrillation, a pervasive cardiac arrhythmia characterized by an irregular and often rapid heartbeat, disrupts the atria’s coordinated contractions, creating a breeding ground for blood clots. The formation of these clots poses a significant threat, as they can dislodge and travel to the brain, precipitating a debilitating ischemic stroke. Current international cardiology guidelines unequivocally endorse the use of oral anticoagulants for AF patients identified as being at high risk of stroke, aiming to mitigate this life-threatening complication. However, for a considerable cohort of patients categorized as having an intermediate stroke risk, the therapeutic landscape has historically been less defined. Anticoagulant intervention in this particular patient subgroup has been positioned as a consideration rather than a firm recommendation, reflecting a lingering uncertainty that has hampered clinical decision-making.
This therapeutic ambiguity stems, in part, from earlier investigations that yielded inconsistent findings, particularly concerning the efficacy and safety of older anticoagulant medications, such as vitamin K antagonists (VKAs). These observational studies, while providing initial insights, were often limited by their design, making it challenging to establish a clear cause-and-effect relationship and potentially introducing confounding factors. The need for robust, prospective evidence to guide treatment strategies for this intermediate-risk AF population became increasingly apparent.
Addressing this critical knowledge gap, the SINGLE-AF trial was conceived and executed with the explicit objective of furnishing the first randomized controlled trial data to rigorously evaluate the benefits of contemporary direct oral anticoagulants (DOACs) in individuals with AF exhibiting an intermediate propensity for stroke. Professor Boyoung Joung, the principal investigator of the SINGLE-AF trial and a distinguished figure from Yonsei University in Seoul, South Korea, highlighted the rationale behind the study: "The evidence derived from observational studies involving anticoagulants, especially vitamin K antagonists, has remained equivocal for patients at intermediate risk. The SINGLE-AF trial was designed to provide the inaugural randomized trial evidence regarding the potential benefits of newer direct oral anticoagulants (DOACs) in patients with AF who possess an intermediate risk of stroke."
The SINGLE-AF study employed an open-label design, a methodological choice that allows both researchers and participants to be aware of the treatment being administered, while still maintaining randomization for objective comparison. The trial was conducted across 18 medical centers situated in South Korea, enrolling a total of 1,803 participants diagnosed with atrial fibrillation. Crucially, these individuals were carefully selected based on their intermediate risk of stroke, as quantified by established clinical scoring systems. Specifically, a CHA2DS2-VASc score of 1 in male patients or 2 in female patients was used to define this intermediate-risk stratum. This rigorous patient selection ensured that the study population accurately represented the group for whom treatment decisions have been most uncertain.
Participants were prospectively allocated in a one-to-one ratio to one of two distinct treatment arms. The experimental group received treatment with modern oral anticoagulants, specifically either apixaban at a dosage of 5 mg administered twice daily or rivaroxaban at a dosage of 20 mg taken once daily. These medications represent the current generation of DOACs, known for their predictable pharmacokinetics and established efficacy profiles. In stark contrast, the control group received no anticoagulant therapy, serving as a baseline against which the effects of DOAC treatment could be measured.
The findings emerging from the 24-month follow-up period were nothing short of remarkable. The trial’s primary composite endpoint, which encompassed a critical combination of stroke, systemic embolism, major bleeding events, and cardiovascular death, revealed a dramatic 69% reduction in occurrence among patients who were administered DOACs when compared to their counterparts who did not receive any anticoagulation. This substantial reduction underscores the profound impact of DOAC therapy in safeguarding this vulnerable patient population.
More granular analysis of the data revealed that serious adverse events transpired in a mere 0.5% of patients receiving DOACs, a stark contrast to the 1.5% observed in the group that did not undergo anticoagulation. This statistically significant difference (p=0.028), reflected by a hazard ratio of 0.31 and a 95% confidence interval of 0.10 to 0.94, strongly suggests a protective effect conferred by the DOAC treatment. The investigation further elucidated that this overarching reduction in serious events was predominantly driven by a significantly lower incidence of ischemic strokes. Ischemic strokes, the most common type of stroke resulting from a blockage in an artery supplying the brain, occurred in only 0.1% of patients on DOAC therapy, compared to a more substantial 1.1% in the untreated cohort. This finding is particularly noteworthy, as stroke prevention is a primary objective in the management of AF.
A critical aspect of anticoagulant therapy is the potential for an increased risk of bleeding. However, the SINGLE-AF trial provided reassuring data on this front. Importantly, the study did not observe an increase in major bleeding events in the group receiving DOAC therapy. Major bleeding occurred in 0.3% of patients on DOACs, a rate comparable to, and indeed slightly lower than, the 0.5% observed in the group not receiving anticoagulation. This finding is crucial for physicians and patients alike, as it suggests that the substantial benefits in preventing thrombotic events can be achieved without a commensurate increase in the risk of dangerous hemorrhages.
The implications of the SINGLE-AF trial’s results are far-reaching and are poised to significantly influence clinical practice and future therapeutic recommendations. The study’s robust randomized evidence provides a clear mandate for the use of newer blood thinners in a segment of the atrial fibrillation population where the advantages of anticoagulation have previously been characterized by uncertainty. Professor Joung articulated the significance of these findings: "We now possess randomized trial evidence demonstrating that patients with AF at intermediate stroke risk derive benefit from DOAC therapy, crucially without an escalation in the incidence of major bleeding. The data generated by the SINGLE-AF trial hold the potential to inform forthcoming guideline recommendations and shape reimbursement policies, thereby facilitating broader access to this effective treatment." This research marks a pivotal moment in the management of atrial fibrillation, offering a more definitive pathway to improved patient outcomes and a reduction in the burden of cardiovascular disease.
About the Author
